Literature DB >> 11331687

The effect of late doses on the achievement of seroprotection and antibody titer levels with hepatitis b immunization among adolescents.

A B Middleman1, C A Kozinetz, L M Robertson, R H DuRant, S J Emans.   

Abstract

OBJECTIVE: To determine the effect of varying dosing schedules and predictor variables on the seroprotection rates and geometric mean titer levels resulting from the hepatitis B vaccination series among adolescents.
METHODS: Adolescents received the hepatitis B vaccination series at varying schedules according to their natural adherence patterns. Data collected included participants' medication use; chronic illness; use of cigarettes, alcohol, and marijuana; age; race/ethnicity; and body mass index. Participants' dates of vaccinations were recorded and titer levels for hepatitis B surface antibody were drawn ~12 and 24 months after study enrollment. The data for 498 participants were analyzed using chi(2) tests, Student t tests, logistic regression models, and analysis of variance.
RESULTS: Seroprotection rates among adolescents were not affected by late vaccinations. The only factors affecting the achievement of seroprotection ~12 and 24 months after the first vaccination were body mass index and the number of immunizations received. Increased time between doses 1 and 2 and doses 2 and 3 showed a trend toward correlating with increasing titer levels.
CONCLUSIONS: Although adolescents at risk of acquiring hepatitis B should receive the hepatitis B vaccination series in a timely fashion, late doses are not detrimental, and may be beneficial, to achieving high antibody levels against the hepatitis B virus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11331687     DOI: 10.1542/peds.107.5.1065

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  5 in total

Review 1.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

Review 2.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 3.  Alternative dosage schedules with HPV virus-like particle vaccines.

Authors:  Margaret A Stanley; Staci L Sudenga; Anna R Giuliano
Journal:  Expert Rev Vaccines       Date:  2014-07-07       Impact factor: 5.217

4.  Seroprevalence to Measles Virus after Vaccination or Natural Infection in an Adult Population, in Italy.

Authors:  Gabriele Anichini; Claudia Gandolfo; Simonetta Fabrizi; Giovan Battista Miceli; Chiara Terrosi; Gianni Gori Savellini; Shibily Prathyumnan; Daniela Orsi; Giuseppe Battista; Maria Grazia Cusi
Journal:  Vaccines (Basel)       Date:  2020-02-03

5.  Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans.

Authors:  Gui-Ping Wen; Linling He; Zi-Min Tang; Si-Ling Wang; Xu Zhang; Yuan-Zhi Chen; Xiaohe Lin; Chang Liu; Jia-Xin Chen; Dong Ying; Zi-Hao Chen; Ying-Bin Wang; Wen-Xin Luo; Shou-Jie Huang; Shao-Wei Li; Jun Zhang; Zi-Zheng Zheng; Jiang Zhu; Ning-Shao Xia
Journal:  Nat Commun       Date:  2020-08-07       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.